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Abstract
OBJECTIVE: This article investigates the methods
of achieving deep remission of inflammatory bowel
disease (IBD).
METHODS: Increasing recognition of the concept
of quality of care is contributing to the evolution of
treatment goals in patients with IBD from clinical re-
sponse and remission (symptom control) toward
deep remission. A change in the treatment goal re-
quires a change in the treatment strategy. Optimi-
zation of conventional therapy, early treatment,
use of the Lemann score, performance of dou-
ble-balloon endoscopy, treatment using Traditional
Chinese Medicine, and good communication be-
tween physicians and patients are needed to attain
deep remission.
RESULTS: The above-mentioned methods can help
to achieve deep remission.
CONCLUSION: Using the above methods, it will be
possible to improve the prognoses of patients with
IBD by minimizing complications and bowel dam-
age and thereby changing the course of the dis-
ease.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
Inflammatory bowel disease (IBD), including Crohn's
disease and ulcerative colitis, is a chronic, progressive,
and destructive disease that is able to induce disability
and severely influence affected patients' quality of life.1
Although IBD is characterized by the alternate occur-
rence of remission and relapse, it may produce persis-
tent inflammation, leading to progressive bowel dam-
age and complications such as stricture, fistulae, and
abscesses. These complications frequently require sur-
gery, which may lead to further disability and higher
mortality.2 Disability among patients with IBD is com-
monly underestimated, but decreased quality of life is
well recognized among affected patients.
The goals of IBD management were formerly focused
on induction and maintenance of symptomatic re-
sponses, and little attention was paid to delay or even
prevention of disease progression.3 However, increasing
recognition of the concept of quality of life has led to
the evolution of treatment goals in IBD from clinical
response and remission (symptom control) toward
deep remission.4 In clinical studies, "deep remission"
means that treatment goals are evolving to encompass
not only symptomatic but also mucosal remission,5
which is defined as a Crohn's disease activating index
(CDAI) of <150 and complete mucosal healing.6
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This paper explores the treatment changes that have de-
veloped with the evolution of the goals of IBD therapy
and discusses the treatment methods necessary to reach
the goal of deep remission.
EVOLUTIONOFTREATMENT GOALS
IN IBD
The evolution of treatment goals in patients with IBD
is potentially changing the course of the disease, the ex-
pectations of patients and healthcare professionals, and
the development of treatment plans. Twenty years ago,
treatment methods for IBD were based on the symp-
toms of the patient, and the point of view that early
treatment would lead to long-term maintenance of re-
mission was put forward.7 This point of view has be-
come the standard of treatment in the form of induc-
tion of remission and its subsequent maintenance. The
provision of personalized medicine is now becoming
possible through, for example, a better understanding
of pharmacogenetics and therapeutic drug monitor-
ing.8 In the future, treatment will be increasingly deter-
mined and optimized according to biotypes based on
genetics, serology, proteomics, metabolomics, individu-
al microbiology, etc.9 In addition, treatment goals have
evolved toward mucosal healing with establishment
and maintenance of deep remission. It is hoped that
achieving these goals will lead to improvements in clini-
cal outcomes, including quality of life, and reductions
in disease-related complications and costs of surgery
and hospitalization. Future goals may include avoid-
ance of corticosteroids, prevention of extraintestinal
complications, and decreased treatment costs.10
Changing treatment goals requires variations in treat-
ment strategies. In conventional approaches, immuno-
modulators are used with a bottom-up strategy based
on clinical outcomes. At present, the aims include in-
duction and maintenance of clinical remission, preven-
tion of disease development and complications, optimi-
zation of surgical outcomes, and prevention of postop-
erative recurrence. Future approaches are likely to in-
volve personalized treatments based on the patient's
prognosis as determined using biological predictors of
response. Future goals will be to increase therapeutic ef-
fects, decrease treatment costs, and prevent disease.
HOWTO IMPROVETHE
MANAGEMENT OF IBDTO ACHIEVE
DEEP REMISSION
Advances in drug development have provided highly ef-
fective treatments to prevent bowel structure damage
in patients with IBD, making deep remission a realistic
goal.11 In fact, anti-TNF therapy achieved deep remis-
sion in a randomized placebo-controlled clinical study,
which also indicates that deep remission is closely asso-
ciated with a significant increase in quality of life and a
significant decrease in the need for hospitalization.
However, translating these goals into everyday practice
requires the implantation of optimized treatment strate-
gies and ongoing monitoring of treatment outcomes.12
In addition, precise definition of the goals themselves
is required, and the long-term benefits associated with
their achievement need to be studied. Furthermore, al-
though effective treatments are available, there remain
many uncertainties about how best to use them.13
Optimization of conventional therapy
Corticosteroids and immunomodulators have been
used in the treatment of IBD for decades, and their ef-
fectiveness is highlighted by the fact that they are rec-
ommended by national and international guidelines.14
However, these agents also have some disadvantages.
Although corticosteroids are very effective, they are not
able to maintain remission, and their side effect profile
makes their long-term use inappropriate. In addition,
the slow action of immunomodulators may not be ade-
quate to induce remission, and their long-term ability
to modify disease has recently been questioned.
Despite these shortcomings, corticosteroids and immu-
nomodulators have been widely used in the treatment
of IBD for many years. However, high-quality evidence
to guide their precise use in terms of dosage, mode of
administration, and duration of therapy is limited.15
High-quality studies showing that corticosteroids effec-
tively induced clinical remission in patients with IBD
were published more than 30 years ago, and the effica-
cy of corticosteroids in IBD has been confirmed in Co-
chrane systematic reviews of controlled studies.16 How-
ever, once remission has been achieved, the goal is to
maintain steroid-free remission. Despite inducing re-
mission in most patients, a prolonged response to corti-
costeroids is observed in less than half of all patients.17
Importantly, corticosteroids are associated with substan-
tial toxicity and should not be continued long-term.
Thus, corticosteroids alone are inadequate for achiev-
ing the proposed treatment goal of deep remission.
They should normally be supplemented and ultimately
replaced by immunomodulators early in the treatment
course.18
Early treatment
The clinical features of IBD have changed in recent
years, with a decreasing frequency of a purely inflam-
matory response and an increasing frequency of a pene-
trating disease leading to the need for surgery. Accord-
ingly, to change the course of the disease, disease-modi-
fying treatments must be prescribed early in the course
of IBD before complications occur.19
There is now increasing clinical evidence to support
the hypothesis that early treatment improves clinical
outcomes in patients with IBD. Recent studies have al-
so demonstrated that early treatment with anti-TNF
therapy is associated with sustained steroid-free remis-
sion and complete mucosal healing.20
However, the identification of patients with early IBD
in clinical practice remains a challenge because no for-
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mal definition exists. An international consensus has
been established to develop a formal definition of early
IBD. The agreed-upon definition is a disease duration
of <18 months in the absence of the use of dis-
ease-modifying agents.21 General acceptance of such a
definition will help establish the widespread use of an
optimized treatment strategy.
New indices in IBD management
Several assessment tools are available for evaluating
IBD symptoms, including the CDAI and Harvey-Brad-
shaw index, but these are often not used routinely in
clinical practice. However, the Lemann score is clinical-
ly useful and can reflect both the extent and severity of
digestive damage.22 To assess the extent of damage, the
digestive tract is considered to be divided into seg-
ments: the upper tract comprises 3 segments, the small
bowel comprises up to 20 segments, the colon and rec-
tum comprise 6 segments, and the anus is considered
to be 1 segment.
As a first step in assessing the severity of damage, each
segment is evaluated separately for strictures, penetrat-
ing lesions, and a history of surgery or other proce-
dures. Each section is graded from no damage to the
most severe damage corresponding to resection, and
based on this evaluation, a score from 0 to 10 is attrib-
uted to each segment.
In the second step, the score per organ is calculated,
which is the sum of the scores in all segments in the or-
gan. Thus, the score per organ would be 0 to 30 for
the upper tract, 0 to 200 for the small bowel, 0 to 60
for the colon/rectum, and 0 to 10 for the anus.
Finally, the scores obtained for each organ are summed
to give an overall score for the entire digestive tract.
The Lemann score is independent of the diagnostic
technique used and allows patients to be assessed at dif-
ferent clinical stages regardless of surgical history or
whether they have limited or extensive disease.
Role of endoscopy in daily clinical practice
Endoscopy plays a key role in the monitoring of IBD.
It allows for assessment of the extent and severity of
the disease, aids treatment decisions, and detects signs
of progression.
Double-balloon endoscopy (DBE) allows for complete
examination of the small bowel, which is important for
determining the extent of mucosal healing.23 Further-
more, it may also be used for biopsies or therapeutic in-
terventions (such as balloon dilatation of strictures)
during DBE. This means that DBE may offer an alter-
native to surgery for some patients. DBE has been suc-
cessfully used to dilate strictures, while endoscopy does
not have this function.
Use of Traditional Chinese Medicine
Acupuncture, a popular procedure in Traditional Chi-
nese Medicine (TCM), has a long history of medical
treatment in China and other Asian countries. It has
been increasingly performed as a complementary and
alternative medical therapy for patients with IBD in
the last 10 to 15 years.24,25 Satisfactory results and posi-
tive effects of both acupuncture and acupuncture com-
bined with Chinese herbal medicine decoctions have
been reported.26
According to TCM theory, spleen "damp-heat", which
is present in many patients with mild to moderate
IBD, cannot strongly promote blood circulation, easily
resulting in "blood stasis". Combined wind and damp-
ness is found to adversely interfere with "Yang Qi", in-
ducing blood stagnation and resulting in thrombosis
and stagnant cold-dampness.27
The TCM treatment principles for IBD are regulation
of Qi activity, promotion and improvement of blood
circulation, and invigoration of the spleen. TCM thera-
py has shown definite effectiveness. At the same time,
because TCM methods involve a long-term treatment
course, they greatly contribute to achieving the aim of
deep remission. In addition, if patients have erosions
that are confined to the colon, even the left-sided co-
lon and mainly ulcerative colitis, treatment comprising
enemas or Chinese medicine suppositories would be
adopted. Such treatments can not only directly reach
the erosions, but also have long-term effects. In TCM,
they are now regarded as important complementary
methods for patients with IBD.
Good communication between physicians and
patients
Good communication between physician and patients
is a cornerstone of effective disease management.28 Af-
ter diagnosis of IBD, patients are likely to feel great un-
certainty about their future. They may be concerned
about the impact of the disease and its treatment on
their daily life, employment prospects, ability to have
children, and later need for hospitalization and surgery.
By proactively discussing these issues, physicians and
the patients can begin to build confidence and estab-
lish an open and long-lasting relationship of trust.
Clear communication regarding the benefits and risks
of alternative management strategies and therapeutic
options is essential throughout the physician-patient re-
lationship. However, physicians must keep in mind
that the management goals that are important to the
patient and the benefits or risks assessed by the patient
may differ from their own. To help reconcile the two
perspectives, the physician must clearly communicate
issues such as the rationale for a long-term manage-
ment plan, the impact of disease progression, steroid
dependence, common and rare potential complications
of surgery, etc. At every decision point, the potential
risk of the treatment (development of complications,
need for surgery, and nutritional problems) must be
carefully balanced against those of overtreatment (an-
ti-TNF-induced toxicity and potential impact on quali-
ty of life).
CONCLUSION
IBD is characterized by sustained inflammation that
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may affect any part of the gastrointestinal tract. Chron-
ic uncontrolled inflammation can lead to the develop-
ment of complications such as stenosis and fistulae, re-
sulting in irreversible structural bowel damage that is
not amenable to medical therapy.29 Such damage is of-
ten associated with the need for surgical removal of
bowel segments. Even during clinical remission, sub-
clinical inflammation may persist and is largely unrec-
ognized, increasing the risk of complications. Treating
physicians must recognize the disconnect between
symptoms and the presence of inflammation, and peri-
odic evaluation of disease activity should be routinely
conducted. It is hoped that complete control of inflam-
mation, timely use of appropriate therapy, strict con-
trol of complications, and minimization of bowel dam-
age will change the course of the disease, improve prog-
noses, and increase the quality of life of affected pa-
tients.
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